在1a期临床试验中,PLN-74809展示出良好的耐受性,药物半衰期潜在支持每日一次给药。除IPF以外,目前还有多种纤维化疾病存在未满足的临床需要,我们希望评估PLN-74809对这些疾病的治疗效果,比如PSC,这是一种慢性进行性疾病,特征是肝脏胆管的炎症和纤维化。原文标题:Pliant Therapeutics Reports Positive Results of Phase 1...
之前在关注名单里排第二 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholan…
Phase 1 studies of PLN-74809 in healthy volunteers have demonstrated good oral bioavailability and tolerability with a t1/2 supportive of once daily dosing.Inhibition of αVβ6-mediated TGF-β activation in the lung by can be detected through measurement of SMAD phosphorylation in alveolar ...
Phase 2 drug target engagement study of PLN-74809 in patients with idiopathic pulmonary fibrosis using a novel αvβ6 cystine knot PET imaging tracer2236 Introduction: Molecular imaging holds great potential to advance our understanding of pulmonary fibrosis and accelerate the development of novel ...
INTEGRIS-PSC phase 2a study: evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitisdoi:10.1016/S0168-8278(23)01037-1Gideon HirschfieldPalak TrivediCynthia LevyChristoph Schramm...